Zongertinib gained both second-line and frontline FDA approval for HER2-mutant NSCLC based on impressive single-arm study data. This unusual path, forgoing traditional randomized Phase III trials, highlights the FDA's willingness to accelerate access to highly effective drugs in areas of high unmet medical need.
Unlike other driver mutations often associated with non-smokers, HER2 mutations in NSCLC occur equally in smokers and never-smokers, as well as across genders and ethnicities. This breaks a common clinical stereotype and underscores the necessity of universal next-generation sequencing for all patients, regardless of their profile.
Despite both Zongertinib and Sevabirtinib showing high efficacy in HER2-mutant NSCLC, Zongertinib's selective nature results in a much better safety profile. Sevabirtinib's dual EGFR/HER2 inhibition leads to significant GI and skin toxicities, making tolerability, not just efficacy, the key factor for clinical preference.
A key clinical strategy for managing the TKI Zongertinib is proactive liver function monitoring. Checking AST/ALT every two weeks for the first three months allows clinicians to intervene with dose holds at the first sign of mild elevations, thereby preventing severe toxicity that would mandate a dose reduction.
Preclinical data shows Sevabirtinib has activity against acquired resistance mutations to Zongertinib. This suggests a future where, similar to the EGFR space, oncologists will use repeat genomic testing to identify resistance mechanisms and rationally sequence different HER2-targeted therapies to extend patient benefit.